Tag

NASDAQ: ALMS

Johnson & Johnson reports at least 72% PASI 90 after two years
Adrian Kessler · Oct 9, 2026
Alumis reports 48‑week scalp and itch data from Phase 3 psoriasis program
Adrian Kessler · Oct 9, 2026
Immunovant drops cutaneous lupus program after IMVT‑1402 trial miss
Adrian Kessler · Sep 23, 2026